Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade

Abstract

Epithelial-mesenchymal plasticity (EMP) of cancer cells contributes to cancer cell heterogeneity, and it is well established that EMP is a critical determinant of acquired resistance to cancer treatment modalities including radiation therapy, chemotherapy, and targeted therapies. Here, we aimed to explore how EMP contributes to cancer cell camouflage, allowing an ever-changing population of cancer cells to pass under the radar of our immune system and consequently compromise the effect of immune checkpoint blockade therapies. The ultimate clinical benefit of any combination regimen is evidenced by the sum of the drug-induced alterations observed in the variety of cellular populations composing the tumor immune microenvironment. The finely-tuned molecular crosstalk between cancer and immune cells remains to be fully elucidated, particularly for the spectrum of malignant cells along the epithelial to mesenchymal axis. High-dimensional single cell analyses of specimens collected in ongoing clinical studies is becoming a key contributor to our understanding of these interactions. This review will explore to what extent targeting EMP in combination with immune checkpoint inhibition represents a promising therapeutic avenue within the overarching strategy to reactivate a halting cancer-immunity cycle and establish a robust host immune response against cancer cells. Therapeutic strategies currently in clinical development will be discussed.

Keywords

Epithelial-to-mesenchymal transition / epithelial-mesenchymal plasticity / immune evasion / tumor immune microenvironment / intrinsic and extrinsic mechanisms of resistance to immune checkpoint blockade / therapeutic opportunity

References

[1] Virchow R.Cellular pathology. As based upon physiological and pathological histology. Lecture XVI--Atheromatous affection of arteries. 1858..Nutr Rev1989;47:23-5

[2] Korniluk A,Kemona H.From inflammation to cancer..Ir J Med Sci2017;186:57-62 PMCID:PMC5323483

[3] Balkwill F.Inflammation and cancer: back to Virchow?.Lancet2001;357:539-45

[4] Thun MJ,Gansler T.Chadwick DJ.Inflammation and cancer: an epidemiological perspective..Cancer and inflammation: novartis foundation symposium 256.2004;Chichester, UKJohn Wiley & Sons, Ltd6-28

[5] Hanahan D.The hallmarks of cancer..Cell2000;100:57-70

[6] Hanahan D.Hallmarks of cancer: the next generation..Cell2011;144:646-74

[7] Ehrlich P.Über den jetzigen Stand der Chemotherapie..Ber Dtsch Chem Ges1909;42:17-47

[8] Burnet FM.The concept of immunological surveillance..Prog Exp Tumor Res1970;13:1-27

[9] Dunn GP,Ikeda H,Schreiber RD.Cancer immunoediting: from immunosurveillance to tumor escape..Nat Immunol2002;3:991-8

[10] Burnet M.Cancer; a biological approach. I. The processes of control..Br Med J1957;1:779-86 PMCID:PMC1973174

[11] Ribatti D.The concept of immune surveillance against tumors. The first theories..Oncotarget2017;8:7175-80 PMCID:PMC5351698

[12] Shankaran V,Bruce AT,Swanson PE.IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity..Nature2001;410:1107-11

[13] Schreiber RD,Smyth MJ.Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion..Science.2011;331:1565-70

[14] Alexandrov LB,Wedge DC,Behjati S.Signatures of mutational processes in human cancer..Nature2013;500:415-21 PMCID:PMC3776390

[15] Rizvi NA,Snyder A,Makarov V.Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer..Science2015;348:124-8 PMCID:PMC4993154

[16] Furuya-Kanamori L,Clark J,Doi SAR.Prevalence of differentiated thyroid cancer in autopsy studies over six decades: a meta-analysis..J Clin Oncol2016;34:3672-9

[17] Coley WB.The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893..Clin Orthop Relat Res1991;2623-11

[18] Coley WB.The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the streptococcus erysipelas and the bacillus prodigiosus)..Proc R Soc Med1910;3:1-48 PMCID:PMC1961042

[19] Kamat AM,Efstathiou JA,Malmström PU.Bladder cancer..Lancet2016;388:2796-810

[20] Knowles MA.Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity..Nat Rev Cancer2015;15:25-41

[21] Krummel MF.CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation..J Exp Med1995;182:459-65 PMCID:PMC2192127

[22] Leach DR,Allison JP.Enhancement of antitumor immunity by CTLA-4 blockade..Science1996;271:1734-6

[23] Hodi FS,McDermott DF,Sosman JA.Improved survival with ipilimumab in patients with metastatic melanoma..N Engl J Med2010;363:711-23 PMCID:PMC3549297

[24] Ishida Y,Shibahara K.Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death..EMBO J1992;11:3887-95 PMCID:PMC556898

[25] Dong H,Tamada K.B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion..Nat Med1999;5:1365-9

[26] Freeman GJ,Iwai Y,Chernova T.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation..J Exp Med2000;192:1027-34 PMCID:PMC2193311

[27] Iwai Y,Tanaka Y,Honjo T.Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade..Proc Natl Acad Sci USA2002;99:12293-7 PMCID:PMC129438

[28] Xiang X,Long D,Zhang S.Prognostic value of PD -L1 expression in patients with primary solid tumors..Oncotarget2018;9:5058-72 PMCID:PMC5797033

[29] Carlsson J,Kosuta V,Giunchi F.PD-L1 expression is associated with poor prognosis in renal cell carcinoma..Appl Immunohistochem Mol Morphol2020;28:213-20

[30] de Vicente JC,Rodrigo JP,Allonca E.PD-L1 expression in tumor cells is an independent unfavorable prognostic factor in oral squamous cell carcinoma..Cancer Epidemiol Biomarkers Prev.2019;28:546-54

[31] Massi D,Merelli B,Xue G.The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600..Ann Oncol2015;26:1980-7

[32] Topalian SL,Brahmer JR,Smith DC.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer..N Engl J Med2012;366:2443-54 PMCID:PMC3544539

[33] Borghaei H,Horn L,Steins M.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer..N Engl J Med2015;373:1627-39 PMCID:PMC5705936

[34] Brahmer J,Baas P,Eberhardt WE.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer..N Engl J Med2015;373:123-35 PMCID:PMC4681400

[35] Powles T,Massard C,Friedlander TW.Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study..JAMA Oncol2017;3:e172411 PMCID:PMC5824288

[36] Three drugs approved for urothelial carcinoma by FDA..Cancer Discov2017;7:659-60

[37] Sharma P,Wargo JA.Primary, adaptive, and acquired resistance to cancer immunotherapy..Cell2017;168:707-23 PMCID:PMC5391692

[38] Hellmann MD,Goldman JW,Borghaei H.Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study..Lancet Oncol2017;18:31-41 PMCID:PMC5476941

[39] Motzer RJ,McDermott DF,Kuzel TM.Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial..J Clin Oncol2015;33:1430-7 PMCID:PMC4806782

[40] Hargadon KM,Williams CJ.Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors..Int Immunopharmacol2018;62:29-39

[41] Syed YY.Durvalumab: first global approval..Drugs2017;77:1369-76 PMCID:PMC5636860

[42] Nishino M,Hatabu H.Monitoring immune-checkpoint blockade: response evaluation and biomarker development..Nat Rev Clin Oncol2017;14:655-68 PMCID:PMC5650537

[43] Schadendorf D,Robert C,Margolin K.Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma..J Clin Oncol2015;33:1889-94 PMCID:PMC5089162

[44] Trotta AM,Scala S.Predictive immune biomarkers: an unattainable chimera?.Cell Mol Immunol2018;15:740-2 PMCID:PMC6141568

[45] Syn NL,Mok TSK.De-novo and acquired resistance to immune checkpoint targeting..Lancet Oncol2017;18:e731-41

[46] Garzón-Orjuela N,Lasalvia P,Castrillón J.Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: a systematic review and network meta-analysis..Dermatol Ther2020;33:e13145

[47] Tray N,Adams S.Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application..Cancer Immunol Res2018;6:1122-8

[48] Schumacher TN.Neoantigens in cancer immunotherapy..Science2015;348:69-74

[49] Galon J.Approaches to treat immune hot, altered and cold tumours with combination immunotherapies..Nat Rev Drug Discov2019;18:197-218

[50] Snyder A,Merghoub T,Zaretsky JM.Genetic basis for clinical response to CTLA-4 blockade in melanoma..N Engl J Med2014;371:2189-99 PMCID:PMC4315319

[51] Van Allen EM,Schilling B,Blank C.Genomic correlates of response to CTLA-4 blockade in metastatic melanoma..Science2015;350:207-11 PMCID:PMC5054517

[52] Chan TA,Jaffee E,Quezada SA.Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic..Ann Oncol2019;30:44-56 PMCID:PMC6336005

[53] Lotsberg ML,Dhakal S,Baguley B.Autophagy mediated danger signaling regulates tumor immunosurveillance and may potentiate the effects of anti-cancer immunotherapy through increased adjuvanticity. Autophagy in immune response: impact on cancer immunotherapy.2020;Elsevier119-40

[54] Klymkowsky MW.Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe..Am J Pathol2009;174:1588-93 PMCID:PMC2671246

[55] Hay ED.An overview of epithelio-mesenchymal transformation..Acta Anat (Basel)1995;154:8-20

[56] Greenburg G.Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells..J Cell Biol1982;95:333-9 PMCID:PMC2112361

[57] Hay ED.Organization and fine structure of epithelium and mesenchyme in the developing chick embryo..Biology1968;

[58] Kalluri R.The basics of epithelial-mesenchymal transition..J Clin Invest2009;119:1420-8 PMCID:PMC2689101

[59] Davis FM,Thompson EW.Targeting EMT in cancer: opportunities for pharmacological intervention..Trends Pharmacol Sci2014;35:479-88

[60] Zhang Y.Epithelial-to-mesenchymal transition in cancer: complexity and opportunities..Front Med2018;12:361-73 PMCID:PMC6186394

[61] Nieto MA,Jackson RA.EMT: 2016..Cell2016;166:21-45

[62] Yang J,Berx G,Brabletz T.Guidelines and definitions for research on epithelial-mesenchymal transition..Nat Rev Mol Cell Biol2020;21:341-52 PMCID:PMC7250738

[63] Thiery JP.Epithelial-mesenchymal transitions in tumour progression..Nat Rev Cancer2002;2:442-54

[64] Nieto MA.The ins and outs of the epithelial to mesenchymal transition in health and disease..Annu Rev Cell Dev Biol2011;27:347-76

[65] Sistigu A,Manic G.Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting..Cytokine Growth Factor Rev2017;36:67-77

[66] Nisticò P,Radisky DC.Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases..Cold Spring Harb Perspect Biol2012;4: PMCID:PMC3281569

[67] Martin M,Lu T.Targeting microenvironment in cancer therapeutics..Oncotarget2016;7:52575-83 PMCID:PMC5239574

[68] Hugo H,Blick T,Clements JA.Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression..J Cell Physiol2007;213:374-83

[69] Tan TZ,Miki Y,Mori S.Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients..EMBO Mol Med2014;6:1279-93 PMCID:PMC4287932

[70] Burger GA,Beltman JB.Deciphering epithelial-mesenchymal transition regulatory networks in cancer through computational approaches..Front Oncol2017;7:162 PMCID:PMC5540937

[71] Thiery JP,Huang RYJ.Epithelial-mesenchymal transitions in development and disease..Cell2009;139:871-90

[72] Li FZ,Anderson RL,Ferrao PT.Phenotype switching in melanoma: implications for progression and therapy..Front Oncol2015;5:31 PMCID:PMC4327420

[73] Caramel J,Hill L,Richard G.A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma..Cancer Cell2013;24:466-80

[74] Richard G,Monet MA,Boespflug A.ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors..EMBO Mol Med2016;8:1143-61 PMCID:PMC5048365

[75] Williams ED,Redfern A.Controversies around epithelial-mesenchymal plasticity in cancer metastasis..Nat Rev Cancer2019;19:716-32 PMCID:PMC7055151

[76] Pastushenko I,Sifrim A,Revenco T.Identification of the tumour transition states occurring during EMT..Nature2018;556:463-8

[77] Gupta PB,Skibinski A,Kuperwasser C.Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance..Cell Stem Cell2019;24:65-78 PMCID:PMC7297507

[78] Boumahdi S.The great escape: tumour cell plasticity in resistance to targeted therapy..Nat Rev Drug Discov2020;19:39-56

[79] Ramirez M,Steininger RJ,Roth MA.Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells..Nat Commun2016;7:10690 PMCID:PMC4762880

[80] Sharma SV,Li B,Takahashi F.A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations..Cell2010;141:69-80 PMCID:PMC2851638

[81] Røsland GV.Novel points of attack for targeted cancer therapy..Basic Clin Pharmacol Toxicol2015;116:9-18 PMCID:PMC4309509

[82] Recondo G,Facchinetti F,Gazzah A.Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer..Clin Cancer Res2020;26:242-55 PMCID:PMC6942925

[83] Shibue T.EMT, CSCs, and drug resistance: the mechanistic link and clinical implications..Nat Rev Clin Oncol2017;14:611-29 PMCID:PMC5720366

[84] Mani SA,Liao MJ,Ayyanan A.The epithelial-mesenchymal transition generates cells with properties of stem cells..Cell2008;133:704-15 PMCID:PMC2728032

[85] Guo W,Donaher JL,Tischler V.Slug and Sox9 cooperatively determine the mammary stem cell state..Cell2012;148:1015-28 PMCID:PMC3305806

[86] Talbot LJ,Kuo PC.Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies..Int J Biochem Mol Biol2012;3:117-36 PMCID:PMC3388731

[87] Ocaña OH,Fabra A,Acloque H.Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1..Cancer Cell2012;22:709-24

[88] Touil Y,Corvaisier M,Vandomme J.Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis..Clin Cancer Res2014;20:837-46 PMCID:PMC4387277

[89] Liau BB,Donohue LK,Flavahan WA.Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance..Cell Stem Cell2017;20:233-46.e7 PMCID:PMC5291795

[90] Hata AN,Archibald HL,Siddiqui FM.Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition..Nat Med2016;22:262-9 PMCID:PMC4900892

[91] Shaffer SM,Torborg SR,Emert B.Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance..Nature2017;546:431-5 PMCID:PMC5542814

[92] Müller J,Tsoi J,Hugo W.Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma..Nat Commun2014;5:5712 PMCID:PMC4428333

[93] Hoek KS,Schlegel NC,Kobert N.In vivo switching of human melanoma cells between proliferative and invasive states..Cancer Res2008;68:650-6

[94] Konieczkowski DJ,Abudayyeh O,Cooper ZA.A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors..Cancer Discov2014;4:816-27 PMCID:PMC4154497

[95] Tirosh I,Prakadan SM,Treacy D.Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq..Science2016;352:189-96 PMCID:PMC4944528

[96] Terry S,Tan TZ,Noman MZ.Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: consequences on susceptibility to cell-mediated cytotoxicity..Oncoimmunology2017;6:e1271858 PMCID:PMC5353930

[97] Bhowmick NA,Bakin A,Lundquist CA.Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism..Mol Biol Cell2001;12:27-36 PMCID:PMC30565

[98] Jokela TA,Rybicka A,Garbe JC.Microenvironment-induced non-sporadic expression of the AXL and cKIT receptors are related to epithelial plasticity and drug resistance..Front Cell Dev Biol2018;6:41 PMCID:PMC5913284

[99] Terry S,Hassan Venkatesh G.Role of hypoxic stress in regulating tumor immunogenicity, resistance and plasticity..Int J Mol Sci2018;19: PMCID:PMC6213127

[100] Hasmim M,Messai Y,Gros G.Cutting edge: hypoxia-induced nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-β1..J Immunol2013;191:5802-6

[101] Noman MZ,Hasmim M.Cytotoxic T cells - stroma interactions..Bull Cancer2011;98:E19-24

[102] Noman MZ.Targeting hypoxia at the forefront of anticancer immune responses..Oncoimmunology2014;3:e954463 PMCID:PMC4353170

[103] Noman MZ,Janji B,Karray S.PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation..J Exp Med2014;211:781-90 PMCID:PMC4010891

[104] Noman MZ,Lequeux A,Duhem C.Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges..Cells2019;8: PMCID:PMC6770817

[105] Chouaib S,Kosmatopoulos K.Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer..Oncogene2017;36:439-45 PMCID:PMC5937267

[106] Dong Y,Wang Z,You Y.Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis..J Hematol Oncol2019;12:112 PMCID:PMC6839087

[107] Gonzalez DM.Signaling mechanisms of the epithelial-mesenchymal transition..Sci Signal2014;7:re8 PMCID:PMC4372086

[108] Horn LA,Palena C.Tumor plasticity and resistance to immunotherapy..Trends Cancer2020;6:432-41 PMCID:PMC7192950

[109] Fiori ME,Villanova L,Stassi G.Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance..Mol Cancer2019;18:70 PMCID:PMC6441236

[110] Huergo-Zapico L,Cantoni C,Fernández-Martínez JL.NK-cell editing mediates epithelial-to-mesenchymal transition via phenotypic and proteomic changes in melanoma cell lines..Cancer Res2018;78:3913-25

[111] Romeo E,Rumio C.The vicious cross-talk between tumor cells with an EMT phenotype and cells of the immune system..Cells2019;8: PMCID:PMC6562673

[112] Wu Y,Rychahou PG,Evers BM.Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion..Cancer Cell2009;15:416-28 PMCID:PMC2881229

[113] Bonde A-K,Kumar S,Schwendener RA.Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors..BMC Cancer2012;12:35 PMCID:PMC3314544

[114] Toh B,Keeble J,Khoo K.Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor..PLoS Biol2011;9:e1001162 PMCID:PMC3181226

[115] Glodde N,van den Boorn-Konijnenberg D,O’Donnell JS.Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy..Immunity2017;47:789-802.e9

[116] Li S,Gao H,Li Z.Tumor-associated neutrophils induce EMT by IL-17α to promote migration and invasion in gastric cancer cells..J Exp Clin Cancer Res2019;38:6 PMCID:PMC6323742

[117] Chen DS.Oncology meets immunology: the cancer-immunity cycle..Immunity2013;39:1-10

[118] Matzinger P.The danger model: a renewed sense of self..Science2002;296:301-5

[119] Garg AD.Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses..Immunol Rev2017;280:126-48

[120] Kroemer G,Kepp O.Immunogenic cell death in cancer therapy..Annu Rev Immunol2013;31:51-72

[121] Gao D.Compound-therapy based on cancer-immunity cycle: promising prospects for antitumor regimens..Am J Cancer Res2019;9:212-8 PMCID:PMC6405975

[122] Zhao T,Jia L,Xin W.Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma..Oncotarget2015;6:2250-62 PMCID:PMC4385849

[123] Akalay I,Hasmim M,Thiery JP.EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction..Autophagy2013;9:1104-6 PMCID:PMC3722321

[124] Lotsberg ML,Terry S,Lu N.AXL targeting abrogates autophagic flux and induces immunogenic cell death in drug-resistant cancer cells..J Thorac Oncol2020;15:973-99 PMCID:PMC7397559

[125] Kroemer G.Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors..Oncotarget2017;8:5686-91 PMCID:PMC5351581

[126] Aguilera TA,Castellini L,Kariolis MS.Reprogramming the immunological microenvironment through radiation and targeting Axl..Nat Commun2016;7:13898 PMCID:PMC5196438

[127] Terry S,Engelsen AST,Dessen P.AXL targeting overcomes human lung cancer cell resistance to NK- and CTL-mediated cytotoxicity..Cancer Immunol Res2019;7:1789-802

[128] Terry S,Ortiz-Cuaran S,Saintigny P.New insights into the role of EMT in tumor immune escape..Mol Oncol2017;11:824-46 PMCID:PMC5496499

[129] Al Absi A,Guerin C,Moreau F.Actin cytoskeleton remodeling drives breast cancer cell escape from natural killer-mediated cytotoxicity..Cancer Res2018;78:5631-43

[130] Kudo-Saito C,Takeuchi T.Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells..Cancer Cell2009;15:195-206

[131] Chouaib S,Tittarelli A,Thiery JP.Tumor plasticity interferes with anti-tumor immunity..Crit Rev Immunol2014;34:91-102

[132] Akalay I,Kumar P,Mami-Chouaib F.Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression..Oncogene2015;34:2261-71

[133] Dongre A,Reinhardt F,Keckesova Z.Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas..Cancer Res2017;77:3982-9 PMCID:PMC5541771

[134] Chen L,Goswami S,Ahn YH.Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression..Nat Commun2014;5:5241 PMCID:PMC4212319

[135] Hugo W,Sun L,Moreno BH.Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma..Cell2016;165:35-44 PMCID:PMC4808437

[136] Thompson JC,Davis C,Jeffries S.Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy..Lung Cancer2020;139:1-8 PMCID:PMC7176049

[137] Wang L,Szabo PM,Castillo-Martin M.EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer..Nat Commun2018;9:3503 PMCID:PMC6115401

[138] Gao J,Zhao H,Xiong L.Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy..Cell2016;167:397-404.e9 PMCID:PMC5088716

[139] Shin DS,Escuin-Ordinas H,Hu-Lieskovan S.Primary resistance to PD-1 blockade mediated by JAK1/2 mutations..Cancer Discov2017;7:188-201 PMCID:PMC5296316

[140] Luke JJ,Sweis RF,Gajewski TF.WNT/β-catenin pathway activation correlates with immune exclusion across human cancers..Clin Cancer Res2019;25:3074-83 PMCID:PMC6522301

[141] Spranger S,Gajewski TF.Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity..Nature2015;523:231-5

[142] Ruiz de Galarreta M,Molina-Sánchez P,Maier B.β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma..Cancer Discov2019;9:1124-41 PMCID:PMC6677618

[143] Grasso CS,Wells DK,Mu XJ.Genetic mechanisms of immune evasion in colorectal cancer..Cancer Discov2018;8:730-49 PMCID:PMC5984687

[144] Trujillo JA,Zha Y,Ritterhouse LL.Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma..J Immunother Cancer2019;7:295 PMCID:PMC6839232

[145] Horn LA,Hempel HA,Lind H.Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity..J Immunother Cancer2020;8: PMCID:PMC7078948

[146] Anandappa AJ,Ott PA.Directing traffic: how to effectively drive T cells into tumors..Cancer Discov2020;10:185-97 PMCID:PMC7007384

[147] Martin CJ,Littlefield C,Chapron C.Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape..Sci Transl Med2020;12:

[148] Yap TA,Araujo DV,Chandana SR.AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors..JCO2020;38:3587

[149] Mariathasan S,Nickles D,Yuen K.TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells..Nature2018;554:544-8 PMCID:PMC6028240

[150] Sow HS,Camps M,Ten Dijke P.Combined inhibition of TGF-β signaling and the PD-L1 immune checkpoint is differentially effective in tumor models..Cells2019;8: PMCID:PMC6523576

[151] Holmgaard RB,Li Y,Murphy MY.Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade..J Immunother Cancer2018;6:47 PMCID:PMC5987416

[152] Tauriello DVF,Stork D,Badia-Ramentol J.TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis..Nature2018;554:538-43

[153] Dodagatta-Marri E,Reeves MQ,To MD.α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas..J Immunother Cancer2019;7:62 PMCID:PMC6399967

[154] Herbertz S,Stauber AJ,Driscoll KE.Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway..Drug Des Devel Ther2015;9:4479-99 PMCID:PMC4539082

[155] Xu G,Wang H,Wang X.Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors..Eur J Med Chem2020;198:112354

[156] Cho BC,Vicente D,Lee DH.Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC)..JCO2020;38:9558

[157] Davidsen KT,Lie MK,Engelsen AST.Akslen LA.The role of axl receptor tyrosine kinase in tumor cell plasticity and therapy resistance..Biomarkers of the tumor microenvironment.2017;ChamSpringer International Publishing351-76

[158] Kirane A,Sorrelle N,Sandal T.Warfarin blocks Gas6-mediated axl activation required for pancreatic cancer epithelial plasticity and metastasis..Cancer Res2015;75:3699-705 PMCID:PMC4572915

[159] Holland SJ,Franci C,Friera AM.Multiple roles for the receptor tyrosine kinase axl in tumor formation..Cancer Res2005;65:9294-303

[160] Taube JH,Komurov K,Gupta S.Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes..Proc Natl Acad Sci USA2010;107:15449-54 PMCID:PMC2932589

[161] Antony J,Kelly Z,Choolani M.The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer..Sci Signal2016;9:ra97

[162] Antony J,Kelly Z,Karali E.The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer..EMBO Rep2018;19: PMCID:PMC6073217

[163] Gay CM,Byers LA.Giving AXL the axe: targeting AXL in human malignancy..Br J Cancer2017;116:415-23 PMCID:PMC5318970

[164] Aguilera TA.Molecular pathways: oncologic pathways and their role in T-cell exclusion and immune evasion-a new role for the AXL receptor tyrosine kinase..Clin Cancer Res2017;23:2928-33 PMCID:PMC5474155

[165] Tanaka M.Axl signaling is an important mediator of tumor angiogenesis..Oncotarget2019;10:2887-98 PMCID:PMC6499597

[166] Sheridan C.First Axl inhibitor enters clinical trials..Nat Biotechnol2013;31:775-6

[167] Liu Y,Ahmed FS,Gettinger SN.Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy..Clin Cancer Res2020;26:970-7 PMCID:PMC7024671

[168] Krebs M,Helland Å,Aix S.P1.01-72 a phase II study of selective AXL inhibitor bemcentinib and pembrolizumab in patients with NSCLC refractory to anti-PD(L)1..J Thorac Oncol2019;14:S388

[169] Shiono A,Mouri A,Hashimoto K.Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients..Thorac Cancer2019;10:775-81 PMCID:PMC6449234

[170] Peeters MJW,Thor Straten P.TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting..Cancer Immunol Immunother2020;69:237-44 PMCID:PMC7000491

[171] Alcántara-Hernández M,Wagar LE,Keler T.High-dimensional phenotypic mapping of human dendritic cells reveals interindividual variation and tissue specialization..Immunity2017;47:1037-50.e6 PMCID:PMC5738280

[172] Maier B,Chen ST,Chang C.A conserved dendritic-cell regulatory program limits antitumour immunity..Nature2020;580:257-62

[173] Rothlin CV,Zuniga EI,Lemke G.TAM receptors are pleiotropic inhibitors of the innate immune response..Cell2007;131:1124-36